ArticleFrontiers in microbiology2025
Drug resistance profile of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A three-phase epidemiological fluctuation framework of extrapulmonary tuberculosis in Fuyang, China: a retrospective study.Frontiers in public health · 2026Article
- Development of a point-of-care dual one-step recombinase-aided PCR assay for rapid identification ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The situation of drug-resistant tuberculosis in China remains serious and complex. The majority of the study data are still derived from the 2,207 national survey of drug-resistant tuberculosis. In this study, we aimed to comprehensively characterize the prevalence of Materials and methods: This study analyzed Results: 55,388 MTB strains collected from 2002 to 2024 were analyzed, among which 15,078 were drug-resistant, including 7,848 multidrug-resistant strains. The resistance rates for INH, RFP, SM, EMB, PZA, and QS were 27.67, 25.33, 11.55, 6.19, 8.63, and 20.63%, respectively. Regional distribution patterns revealed that the eastern and western regions had the highest number of strains, but relatively low resistance rates. There was a low inflection point in 2019 for the resistance rates of all drugs except INH, whose resistance rate continued to increase after 2017. A total of 754 non-synonymous mutations were identified, with the highest mutation rates observed in INH (32.91%), RIF (28.98%), and QS (14.47%). The dominant mutation sites were Conclusion: Our analysis demonstrates that drug-resistant tuberculosis remains a serious challenge in China. Newly identified resistance-conferring mutations should be prioritized and integrated with the specific epidemiological characteristics of DR-TB in China to support the development and implementation of rapid diagnostic technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.